See more : D2L Inc. (DTLIF) Income Statement Analysis – Financial Results
Complete financial analysis of LadRx Corporation (LADX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of LadRx Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- RUNBEN BIOTECHNOLOGY (603193.SS) Income Statement Analysis – Financial Results
- Three Sixty Solar Ltd. (VSOLF) Income Statement Analysis – Financial Results
- Beyond Meat, Inc. (BYND) Income Statement Analysis – Financial Results
- Banque nationale de Belgique Société anonyme (BNB.BR) Income Statement Analysis – Financial Results
- Zaggle Prepaid Ocean Services Limited (ZAGGLE.BO) Income Statement Analysis – Financial Results
LadRx Corporation (LADX)
About LadRx Corporation
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 250.00K | 100.00K | 200.00K | 100.00K | 100.00K | 300.00K | 100.00K | 250.00K | 100.00K | 9.50M | 6.27M | 7.46M | 2.07M | 184.36K | 428.16K | 94.00K | 1.34M | 4.40M | 3.33M | 823.00K | 1.30M | 14.30M | 2.90M | 2.50M | 2.50M | 4.50M | 2.50M | 4.80M | 1.10M | 500.00K | 900.00K | 700.00K |
| Cost of Revenue | 11.84K | 15.00K | 13.98K | 29.04K | 20.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.29K | 70.50K | -49.94K | 217.00K | -300.00K | 6.40M | 1.60M | 800.00K | -300.00K | -100.00K | 0.00 | 0.00 | 700.00K | 2.20M | 0.00 | 0.00 |
| Gross Profit | -11.84K | -15.00K | -13.98K | -29.04K | -20.66K | 250.00K | 100.00K | 200.00K | 100.00K | 100.00K | 300.00K | 100.00K | 250.00K | 100.00K | 9.50M | 6.27M | 7.46M | 2.07M | 184.36K | 428.16K | 94.00K | 1.33M | 4.33M | 3.38M | 606.00K | 1.60M | 7.90M | 1.30M | 1.70M | 2.80M | 4.60M | 2.50M | 4.80M | 400.00K | -1.70M | 900.00K | 700.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.16% | 98.40% | 101.50% | 73.63% | 123.08% | 55.24% | 44.83% | 68.00% | 112.00% | 102.22% | 100.00% | 100.00% | 36.36% | -340.00% | 100.00% | 100.00% |
| Research & Development | 279.49K | 0.00 | 0.00 | 799.58K | 403.01K | 388.84K | 19.84M | 35.93M | 43.40M | 36.68M | 17.50M | 12.68M | 15.49M | 8.51M | 7.54M | 10.47M | 18.82M | 9.78M | 9.09M | 6.01M | 4.39M | 767.10K | 1.84M | 1.96M | 12.81M | 7.30M | 5.60M | 3.10M | 7.10M | 6.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.33M | 4.55M | 5.97M | 6.00M | 7.44M | 8.08M | 12.50M | 15.99M | 19.66M | 12.85M | 10.27M | 8.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 200.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.53M | 4.55M | 5.97M | 6.00M | 7.44M | 8.08M | 12.50M | 15.99M | 19.66M | 12.85M | 10.27M | 8.35M | 7.32M | 8.24M | 9.13M | 10.93M | 14.82M | 9.66M | 6.42M | 7.90M | 6.99M | 3.88M | 3.42M | 2.25M | 3.78M | 2.50M | 8.80M | 4.50M | 3.50M | 3.50M | 7.70M | 5.00M | 2.50M | 1.30M | 2.10M | 6.00M | 3.50M |
| Other Expenses | 11.84K | -2.62K | -7.21M | 10.07K | -12.52K | 2.68K | -16.32K | 159.15K | 20.15K | 132.11K | 183.03K | 191.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.82M | 4.56M | 5.98M | 6.83M | 7.86M | 8.50M | 32.97M | 52.46M | 63.38M | 49.71M | 27.89M | 21.15M | 22.90M | 16.85M | 17.15M | 22.02M | 33.92M | 19.67M | 15.73M | 14.02M | 11.38M | 5.78M | 5.26M | 4.53M | 16.66M | 10.30M | 15.20M | 8.30M | 11.20M | 10.70M | 7.90M | 5.10M | 2.60M | 1.40M | 2.60M | 6.60M | 3.80M |
| Cost & Expenses | 3.82M | 4.56M | 5.98M | 6.83M | 7.86M | 8.50M | 32.97M | 52.46M | 63.38M | 49.71M | 27.89M | 21.15M | 22.90M | 16.85M | 17.15M | 22.02M | 33.92M | 19.67M | 15.73M | 14.02M | 11.38M | 5.79M | 5.33M | 4.48M | 16.88M | 10.00M | 21.60M | 9.90M | 12.00M | 10.40M | 7.80M | 5.10M | 2.60M | 2.10M | 4.80M | 6.60M | 3.80M |
| Interest Income | 55.43M | 11.69K | 16.82K | 119.27K | 351.97K | 355.56K | 365.58K | 255.12K | 233.96K | 305.33K | 137.68K | 131.67K | 207.22K | 303.59K | 349.49K | 1.20M | 0.00 | 996.65K | 206.20K | 0.00 | 82.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.72M | 3.83M | 2.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.84K | 15.00K | 13.98K | 29.04K | 20.66K | 29.42K | 106.99K | 536.63K | 317.65K | 182.93K | 120.40K | 113.94K | 95.52K | 107.67K | 475.32K | 624.98K | 272.23K | 227.70K | 217.10K | 103.85K | 2.13K | 1.13M | 586.25K | 317.85K | 68.00K | 500.00K | 800.00K | 700.00K | 600.00K | 400.00K | 200.00K | 100.00K | 100.00K | 100.00K | 500.00K | 600.00K | 300.00K |
| EBITDA | 412.28K | -4.55M | -13.16M | -6.80M | -7.84M | -7.33M | -26.51M | -47.48M | -62.96M | -29.93M | -27.47M | -20.94M | -22.56M | -16.64M | -7.17M | -15.13M | -26.19M | -17.37M | -15.33M | -13.49M | -11.28M | -3.32M | -345.09K | -829.61K | -15.20M | -7.19M | -4.70M | -2.80M | -8.90M | -7.50M | -3.10M | -2.50M | 2.30M | -900.00K | -3.80M | -5.10M | -2.80M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,144.19% | -31,892.89% | -25,653.37% | -67,398.11% | -68,474.18% | -2,421.46% | -23,704.50% | -12,271.48% | -17,672.18% | -96.26% | -117.13% | -371.15% | -840.85% | -8,402.38% | -2,443.93% | -12,002.41% | -143.08% | -7.84% | -24.93% | -2,072.78% | -723.08% | -55.24% | -258.62% | -312.00% | -300.00% | -68.89% | -196.00% | 41.67% | -90.91% | -760.00% | -600.00% | -528.57% |
| Operating Income | -3.82M | -4.56M | -12.08M | -6.83M | -7.52M | -7.89M | -32.52M | -51.84M | -67.72M | -68.66M | -27.59M | -23.82M | -22.65M | -16.75M | -7.64M | -23.77M | -26.46M | -17.60M | -15.54M | -16.61M | -11.28M | -4.45M | -931.34K | -1.15M | -16.06M | -8.70M | -7.30M | -7.00M | -9.50M | -7.90M | -3.30M | -2.60M | 2.20M | -1.00M | -4.30M | -5.70M | -3.10M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,155.96% | -32,522.20% | -25,921.68% | -67,715.76% | -68,657.10% | -9,198.15% | -23,818.43% | -9,061.59% | -16,750.60% | -80.47% | -379.33% | -354.73% | -852.02% | -8,431.39% | -3,879.77% | -12,004.68% | -331.42% | -21.17% | -34.48% | -1,951.15% | -669.23% | -51.05% | -241.38% | -380.00% | -316.00% | -73.33% | -104.00% | 45.83% | -90.91% | -860.00% | -633.33% | -442.86% |
| Total Other Income/Expenses | 4.22M | 360.32K | -1.10M | 129.35K | 339.45K | -830.34K | -2.09M | 1.07M | 4.69M | 19.49M | -19.89M | 3.09M | 8.33M | 17.16M | 2.33M | -10.50M | 4.61M | 993.44K | 369.80K | -2.96M | -6.66M | -1.73M | 0.00 | 0.00 | 280.92K | 191.41K | 1.40M | -2.30M | -1.10M | 0.00 | 0.00 | 2.40M | 300.00K | 100.00K | 0.00 | 300.00K | 900.00K |
| Income Before Tax | 400.44K | -4.20M | -13.18M | -6.70M | -7.52M | -9.08M | -34.99M | -50.77M | -58.59M | -30.12M | -47.48M | -17.96M | -14.33M | 408.46K | -5.32M | -26.17M | -21.85M | -16.61M | -15.38M | -19.63M | -17.95M | -6.18M | -931.34K | 0.00 | -14.99M | -7.50M | -5.90M | -5.80M | -10.60M | 0.00 | 0.00 | -200.00K | 2.50M | -900.00K | 0.00 | -5.40M | -2.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,631.44% | -34,985.63% | -25,385.21% | -58,586.39% | -30,117.18% | -15,827.95% | -17,962.27% | -5,730.62% | 408.46% | -55.99% | -417.69% | -292.93% | -803.93% | -8,342.65% | -4,585.56% | -19,091.94% | -460.21% | -21.17% | 0.00% | -1,821.26% | -576.92% | -41.26% | -200.00% | -424.00% | 0.00% | 0.00% | -8.00% | 52.08% | -81.82% | 0.00% | -600.00% | -314.29% |
| Income Tax Expense | 0.00 | -362.05K | -16.41K | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 1.60K | 1.60K | 98.00K | -1.33M | -519.16K | 873.00K | 40.00K | 145.00K | -451.25K | 2.80M | -101.83K | 1.40M | 0.00 | -799.36K | -1.02M | -2.40M | -1.30M | -1.20M | 1.20M | -200.00K | -100.00K | -2.50M | -300.00K | -100.00K | 500.00K | -1.00M | -1.00M |
| Net Income | 400.44K | -4.20M | -13.18M | -6.70M | -7.16M | -12.71M | -34.99M | -50.77M | -58.59M | -30.12M | -47.49M | -17.96M | -14.42M | 408.46K | -4.80M | -27.05M | -21.89M | -16.75M | -15.09M | -16.39M | -17.84M | -6.18M | -931.34K | -348.10K | -15.04M | -6.30M | -6.00M | -5.80M | -10.70M | -7.70M | -3.20M | -100.00K | 2.50M | -900.00K | -4.80M | -4.70M | -2.10M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,085.44% | -34,986.43% | -25,385.61% | -58,587.19% | -30,117.98% | -15,828.48% | -17,963.87% | -5,769.82% | 408.46% | -50.53% | -431.62% | -293.47% | -810.95% | -8,186.62% | -3,828.48% | -18,983.62% | -460.21% | -21.17% | -10.46% | -1,827.58% | -484.62% | -41.96% | -200.00% | -428.00% | -308.00% | -71.11% | -4.00% | 52.08% | -81.82% | -960.00% | -522.22% | -300.00% |
| EPS | 0.68 | -968.78 | -3.51K | -1.93K | -2.15K | -41.08 | -145.52 | -375.79 | -581.19 | -332.36 | -866.24 | -469.17 | -482.54 | 18.00 | -201.66 | -1.24K | -1.09K | -1.03K | -1.12K | -2.01K | -2.74K | -1.62K | -377.67 | -155.19 | -8.26K | -3.47K | -3.18K | -3.15K | -5.67K | -3.95K | -1.72K | -55.99 | 2.02K | -840.34 | -4.71K | -3.57K | -1.68K |
| EPS Diluted | 0.68 | -968.78 | -3.51K | -1.93K | -2.15K | -41.08 | -145.52 | -375.79 | -581.19 | -332.36 | -866.24 | -469.17 | -482.54 | 18.00 | -201.66 | -1.24K | -1.09K | -1.03K | -1.12K | -2.01K | -2.74K | -1.62K | -377.67 | -155.19 | -8.26K | -3.47K | -3.18K | -3.15K | -5.58K | -3.95K | -1.72K | -55.99 | 2.02K | -840.34 | -4.71K | -3.57K | -1.68K |
| Weighted Avg Shares Out | 488.39K | 4.34K | 3.76K | 3.47K | 3.33K | 309.48K | 240.42K | 135.11K | 100.81K | 90.62K | 54.82K | 38.29K | 29.89K | 26.07K | 23.80K | 21.76K | 20.00K | 16.22K | 13.54K | 8.17K | 6.51K | 3.81K | 2.47K | 2.24K | 1.82K | 1.82K | 1.89K | 1.84K | 1.89K | 1.95K | 1.86K | 1.79K | 1.24K | 1.07K | 1.02K | 1.32K | 1.25K |
| Weighted Avg Shares Out (Dil) | 488.39K | 4.34K | 3.76K | 3.47K | 3.33K | 309.48K | 240.42K | 135.11K | 100.81K | 90.62K | 54.82K | 38.29K | 29.89K | 26.53K | 23.80K | 21.76K | 20.00K | 16.22K | 13.54K | 8.17K | 6.51K | 3.81K | 2.47K | 2.24K | 1.82K | 1.82K | 1.89K | 1.84K | 1.92K | 1.95K | 1.86K | 1.79K | 1.24K | 1.07K | 1.02K | 1.32K | 1.25K |
LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company is restarting a process to seek marketing approval of aldoxorubicin under...
Source: https://incomestatements.info
Category: Stock Reports